Gestion des effets secondaires des thérapies ciblées dans le cancer du rein : thérapies ciblées et effets secondaires dermatologiques
作者： Caroline Robert , Pierre Gimel
关键词:
摘要: Resume Les therapies moleculaires ciblees (TMC) telles que les inhibiteurs de l'angiogenese ou mTOR administrees dans le cancer du rein avance peuvent induire une multitude d'effets secondaires affectant la peau, cheveux et ongles. Ces recommandations decrivent l'incidence, presentation clinique traitements necessaires pour prendre en charge effets dermatologiques survenant avec TMC (sunitinib, sorafenib, pazopanib, bevacizumab, everolimus temsirolimus).
sci-hub.st 参考文章(32)
Caroline Robert, Effets secondaires cutanés des molécules anti-angiogéniques Bulletin Du Cancer. ,vol. 94, pp. 260- 264 ,(2007) , 10.1684/BDC.2007.0417
J. Beck, I. Procopio, S. Negrier, D. Keilholz, C. Sczylik, C. Bokemeyer, U.P. Strauss, K. Burock, S. Mersmann, B. Escudier, 7137 Final analysis of a large open-label, noncomparative, phase 3 study of sorafenib in European patients with advanced RCC (EU-ARCCS) Ejc Supplements. ,vol. 7, pp. 434- 435 ,(2009) , 10.1016/S1359-6349(09)71470-3
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Rongcheng Luo, Jifeng Feng, Shenglong Ye, Tsai-Sheng Yang, Jianming Xu, Yan Sun, Houjie Liang, Jiwei Liu, Jiejun Wang, Won Young Tak, Hongming Pan, Karin Burock, Jessie Zou, Dimitris Voliotis, Zhongzhen Guan, None, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology. ,vol. 10, pp. 25- 34 ,(2009) , 10.1016/S1470-2045(08)70285-7
Bernard Escudier, Tim Eisen, Walter M Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Negrier, Christine Chevreau, Ewa Solska, Apurva A Desai, Frédéric Rolland, Tomasz Demkow, Thomas E Hutson, Martin Gore, Scott Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M Bukowski, None, Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine. ,vol. 356, pp. 125- 134 ,(2007) , 10.1056/NEJMOA060655
J. Autier, C. Mateus, J. Wechsler, A. Spatz, C. Robert, Effets secondaires cutanés du sorafenib et du sunitinib Annales De Dermatologie Et De Venereologie. ,vol. 135, pp. 148- 153 ,(2008) , 10.1016/J.ANNDER.2007.12.006
Naeem Bhojani, Claudio Jeldres, Jean-Jacques Patard, Paul Perrotte, Nazareno Suardi, Georg Hutterer, François Patenaude, Stéphane Oudard, Pierre I. Karakiewicz, Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma European Urology. ,vol. 53, pp. 917- 930 ,(2008) , 10.1016/J.EURURO.2007.11.037
Catherine Guevremont, Ahmed Alasker, Pierre I Karakiewicz, Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Current Opinion in Supportive and Palliative Care. ,vol. 3, pp. 170- 179 ,(2009) , 10.1097/SPC.0B013E32832E4681
Caroline Robert, Sandrine Faivre, Eric Raymond, Jean-Pierre Armand, Bernard Escudier, Subungual Splinter Hemorrhages: A Clinical Window to Inhibition of Vascular Endothelial Growth Factor Receptors? Annals of Internal Medicine. ,vol. 143, pp. 313- 314 ,(2005) , 10.7326/0003-4819-143-4-200508160-00021
Jean Philippe Arnault, Janine Wechsler, Bernard Escudier, Alain Spatz, Gorana Tomasic, Vincent Sibaud, Selim Aractingi, Jean-Didier Grange, Vichnou Poirier-Colame, David Malka, Jean-Charles Soria, Christine Mateus, Caroline Robert, Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib Journal of Clinical Oncology. ,vol. 27, ,(2009) , 10.1200/JCO.2009.23.4823
Christopher W. Ryan, Bryan H. Goldman, Primo N. Lara, Philip C. Mack, Tomasz M. Beer, Catherine M. Tangen, Dianne Lemmon, Chong-Xian Pan, Harry A. Drabkin, E. David Crawford, Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group Journal of Clinical Oncology. ,vol. 25, pp. 3296- 3301 ,(2007) , 10.1200/JCO.2007.11.1047